A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
暂无分享,去创建一个
Michael Ames | Kurt Hertogs | K. Hertogs | W. Verbiest | C. Farthing | N. Graham | C. Cohen | M. Conant | S. Hunt | M. Sension | S. Jacobson | J. Nadler | M. Ames | A. Rinehart | Charles Farthing | Marcus Conant | Alex R Rinehart | Calvin J Cohen | Susan Hunt | Michael Sension | Susan Jacobson | Jeffrey Nadler | Werner Verbiest | Neil M Graham
[1] R. Siliciano,et al. Viral Dynamics in HIV-1 Infection , 1998, Cell.
[2] P. Tebas,et al. Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. , 1999, AIDS.
[3] Brendan Larder,et al. A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs , 1998, Antimicrobial Agents and Chemotherapy.
[4] C. Briones,et al. Introduction of HIV drug-resistance testing in clinical practice. , 1999, AIDS.
[5] Martin A. Nowak,et al. Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.
[6] Pierre-Marie Girard,et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial , 2002, AIDS.
[7] R. Chaisson,et al. Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.
[8] D. Richman,et al. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients , 1996, Journal of virology.
[9] B. Larder,et al. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates , 1994, Antimicrobial Agents and Chemotherapy.
[10] H. Vahaboğlu,et al. Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. , 1998, The Journal of antimicrobial chemotherapy.
[11] P. Harrigan,et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. , 1999, AIDS.
[12] J. Condra,et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.
[13] S. Hammer,et al. The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan , 2000, Antiviral therapy.
[14] B. Larder,et al. Mutations in Retroviral Genes Associated with Drug Resistance , 1996 .
[15] J. Leonard,et al. The duration of viral suppression during protease inhibitor therapy for HIV‐1 infection is predicted by plasma HIV‐1 RNA at the nadir , 1998, AIDS.
[16] Richard A. Loftus,et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.
[17] T. Merigan,et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy , 2000 .
[18] R. Grant,et al. Activity of a ritonavir plus saquinavir‐containing regimen in patients with virologic evidence of indinavir or ritonavir failure , 1998, AIDS.
[19] J. Schapiro,et al. Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial , 1999, The Lancet.
[20] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.